SoluFlex Link™ ADC Platform

Features of the
SoluFlex Link™ Hydrophilic Linkers

Our new linker structure allows for ADCs with a DAR¹ of 8 and improves hydrophilicity to a level very similar to unconjugated antibodies.
This new branched linker structure with high hydrophilicity minimizes the solution exposure of hydrophobic payloads.

HIC-HPLC Chromatogram Data³

HIC-HPLC Chromatogram Data

Branched Solubilizing Linker

Compatible with all cleavable and non-cleavable linkers and payloads (Branched linker flexibility)
Improved hydrophilicity (Superior to PEG in hydrophilic properties)
Optimized pharmacokinetic (PK) profile
Low immunogenicity potential
High conjugation and purification yields
Thermal stability, freeze/thaw stability
Target dependent in vitro efficacy
No toxic metabolites

1.DAR : Drug-to-antibody ratio
2.Poly Ethylene Glycol
3.Using Exatecan-Topo 1 inhibitor drug

LOTTE Biologics leverages its ADC platform to offer a diverse combination of payloads and linkers through its ADC Toolbox service.
We have designed an optimized ADC Toolbox that enables the selection of lead candidate linker-payload combinations to enhance clinical trial success rates, accelerating the
development of our clients' programs.

Antibody

Conjugating unit

Site-specific conjugation
Other (Applicable to all conjugating units)

SoluFlex Link™-Linker

SoluFlex Link™
With Cleavable linkers
1. Val-Cit
2. Val-Ala
3. Phe-Gly
4. β-Glucuronide
With Non-cleavable linkers
1. MC
2. MP
Other (Applicable to all linkers)

Payload (Novel & Derivatives)

SoluFlex Link™ Linker with
Nemorubicin analog (Novel)*
Nemorubicin : DNA damaging agent
Exatecan : Topoisomerase I inhibitor
Ispinesib : Kinesin inhibitor (KSP)
Attenuated PBD dimer : DNA Alkylating agent
Duocarmycin DM analog : DNA Alkylating agent
Seco DUBA analog : DNA Alkylating agent
MMAE : Microtubule inhibitor
MMAF : Microtubule inhibitor
Other (Applicable to all payloads)

* Demonstrated low conversion to toxic metabolites